Tianjin Institute of Pharmaceutical Research Co., Ltd.

Tianjin Institute of Pharmaceutical Research

Andon Health Co., Ltd.

Tasly Holding Group Co., Ltd.

Huafeng (Tianjin) New Material Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Wei Liu

Lida Tang

Weiren Xu

Guilong Zhao

Yuquan Li

Yuli Wang

Meixiang Zou

Yuqiang Liu

Yafei Xie

Changying Liu

Haizhi Zhang

Huihui Chen

Jingwei Wu

Bingni Liu

Xuyuan Liu

Chubing Tan

Hua Shao

Qian Shang

Jialiang Zhang

Peng Liu

Renda Wang

Jianming Chen

Shijun Zhang

Lina Wang

Naxia Zhao

Yiliang Li

Ye Sun

Baoan Gao

Yingmei Han

Guangping Xia

Zhixing Zhou

Chuan Li

Guofeng Tong

Weiling Kong

Jing Jin

Xiaohua Kong

Zhensheng Li

Mengjun Liu

Li Deng

Qiuxia Yang

Jing Sun

Peng Gu

Yingying Zhang

Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: wherein the definitions of X, X, X, X, X, X, X, X, X, X, X, X, X, Xand Xare consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Glucagon-derived peptide and use thereof

A preparation method for a silica aerogel, comprising the following steps: A) raw material containing a solid silicon source and an alkaline solution is used to produce an aerogel precursor after mixing; and B) the aerogel precursor is dried to obtain a silica aerogel. An improved silica aerogel preparation method, comprising the following steps: A) a cation exchange resin and a silicate solution are used as raw materials and mixed; B) the mixed material is allowed to stand to obtain an aerogel precursor; and C) the aerogel precursor is dried to obtain a silica aerogel.

Silica aerogel preparation method and aerogel prepared using said method

Infrared thermometer

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

Crystal form of urate transporter 1 inhibitor and preparation method and use thereof

Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization. 

Method for preparing urate transporter 1 inhibitor

The present invention relates to the pharmaceutical field for the treatment of hyperuricemia and gout. In particular, the present invention relates to a carboxylic acid urate transporter 1 (URAT1) inhibitor of a general formula (I) containing a diarylmethane structure and a preparation method thereof, and a pharmaceutical composition containing the same and a use thereof in the preparation of medicaments for treating hyperuricemia and gout, 

Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof

A pharmaceutical solution of taxanes, its preparation method, a composition comprising said solution and its pharmaceutical combination package are disclosed. Said pharmaceutical solution comprises taxanes, a pH regulator and a solvent, wherein the pH regulator is a water-soluble acid.

Pharmaceutical solution of taxanes comprising pH regulator and preparation method thereof

The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof, wherein, the definitions of Rand Rare selected from the following: (1) R5=R6=Me; (2) R5=Me, R6=OMe; (3) R5=Me, R6=H; (4) R5=Me, R6=F; (5) R5=F, R6=H; and (6) R5=OMe, R6=H. 

Phenyl C-glucoside derivatives, preparation methods and uses thereof

The present invention relates to the field of drugs associated with treating diabetes. Particularly, the present invention relates to a dipeptidyl peptidase-IV inhibitor having the structure shown by formula (I), which contains amide thiazole structure and has an effect on treating diabetes, and a preparation method and a pharmaceutical composition containing it, as well as use thereof in manufacture of the drugs for treating the diabetes, wherein, Ris methyl; Ris phenyl; phenyl, 2-thienyl substituted in a mono-substituted, bi-substituted manner by fluorine and methyl.

Amide thiazole derivative, preparation method and uses thereof

Growing community of inventors

Tianjin, China

Wei Liu